Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPWPZdLPDhiaB?= NHz3fVNKSzVyPUGzPU4zOOLCidMx5qCKPS57NTFOwG0> NEPye|IzPTl4MEK4Ni=>
KellyCis83 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3yOFghcA>? MWXJR|UxRTJ3MT6wNQKBkcLz4pEJNVUvPzVizszN M{nPSVI2QTZyMkiy
SK-N-AS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L6TlQ5KGh? M4Tr[WlEPTB;MkK3Mlcx6oDLwsJihKkzOi5zNTFOwG0> MkDENlU6PjB{OEK=
SK-N-ASCis24 NWPD[Jk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXu0PEBp NWfYZWRPUUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? M1LHPVI2QTZyMkiy
CHP-212 NXXQO2xzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUS0PEBp MXvJR|UxRTdwOUhihKnDueLCiUCuOlkh|ryP NIXJSZQzPTl4MEK4Ni=>
CHP-212Cis100 M3HOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHLfYo1QCCq Ml;lTWM2OD17LkW15qCKyrIkgJmwMlg5KM7:TR?= MWWyOVk3ODJ6Mh?=
U87  MV3GeY5kfGmxbjDBd5NigQ>? MXmxNFAh|ryP MXuyOE04OiCq NF\5SnhqdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?= MmTyNlU5ODh6Nki=
LN229 NX;t[XY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi1NE02OCEQvF2= NU[0c2JjUUN3ME2xOkDPxE1? M{L0Z|I2PzVyMkez
TR-LN229 NFO0VIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfoNE02OCEQvF2= MYXJR|UxRTd5IN88US=> NVKwfmJpOjV5NUCyO|M>
U87  M4[1RmFxd3C2b4Ppd{BCe3OjeR?= M3jGfFDjiJN{MEFihKnDvU1? M{[0T|I1KGh? M4fMV4VvcGGwY3XzJGNSKGmwZIXj[YQh[XCxcITvd4l{ MVGyOVY5OTZ4OB?=
U251MG M{jTV2Fxd3C2b4Ppd{BCe3OjeR?= M3vEWVExOMLizszN MojUOFghcA>? M4PoeXBDWw>? Mn7DbY5lfWOnczDhdI9xfG:|aYO= M2nqU|I2PjhyNE[0
U87MG NGTGS4FCeG:ydH;zbZMhSXO|YYm= MlzqNVAxyqEQvF2= M3XTSlQ5KGh? MULQRnM> MlLxbY5lfWOnczDhdI9xfG:|aYO= MVWyOVY5ODR4NB?=
U87 NHvmcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\GOVAuOzVyIN88US=> M33BPFQ5yqCqwrC= MXrpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> M3;tZ|I2PTV2MkKz
U118  MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi1empNPTBvM{WwJO69VQ>? M4LCR|Q5yqCqwrC= NETDVG9qdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? MXKyOVU2PDJ{Mx?=
U87 NIW3dFBHfW6ldHnvckBCe3OjeR?= MWmyOVAwOzVyIN88US=> NWTJW5FwPDkEoHlCpC=> NWDaS|Z{\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn MU[yOVU2PDJ{Mx?=
U118  NV:ySHFYTnWwY4Tpc44hSXO|YYm= NVfwO3Z3OjVyL{O1NEDPxE1? MkT3OFjDqGkEoB?= Ml;5[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm NGnoeVYzPTV3NEKyNy=>
U87 M2f2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMS|I2OC9|NUCg{txO MX60POKhcMLi M2HVeIlv[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBUKGGwZDDHNk9OyqClb4Ty[YF1\WRid3n0bEBVVVh? NFPGVW4zPTV3NEKyNy=>
A375 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS0V2o1QMLiaNMg NV21[Zl6UUN3ME2yOlUh|ryP MXOyOVUzPDV3Mh?=
A2058 NIjETG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzvb3pyPDkEoHlCpC=> MljKTWM2OD1zMjFOwG0> MofwNlU2OjR3NUK=
M238 NF70[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETq[GE1QMLiaNMg NXexc5RYUUN3ME20NEDPxE1? MX[yOVUzPDV3Mh?=
M249 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD0OFjDqGkEoB?= MYjJR|UxRTJ3NDFOwG0> M3zHPFI2PTJ2NUWy
M21 NYX0V4lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrGOFjDqGkEoB?= NFrM[5lKSzVyPUKyNUDPxE1? M2PqZ|I2PTJ2NUWy
U251 MlXiR5l1d3SxeHn0fUBCe3OjeR?= M{T4[VIxKM7:TdMg NYHIbIJQPDkEoHlCpC=> MmjKdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= MlzTNlU1OzR|OEG=
LN229 M13XS2N6fG:2b4jpeJkhSXO|YYm= NFPmO2szOCEQvF5CpC=> MoS0OFjDqGkEoB?= MkC5doVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= M37MZVI2PDN2M{ix
U373MG-LUC M3v0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3kO|IhcA>? MXLJR|UxRjZyMDFOwG0> M{LPcVI2PDNzOUWz
U87  M2jMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnUboozPS1{MECg{txO NX7LSIdCPDkEoHlCpC=> NGLxU5lqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVyyOVQxODd2NR?=
U251 NEXmPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qxT|I2NTJyMDFOwG0> M2\1dlQ5yqCqwrC= NFTpS2NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn;NNlU1ODB5NEW=
U251 NF\oflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[xNFAuPDByIN88US=> MnH1O|IwQTZiaB?= MYH0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NUnXdGI6OjV|N{WyO|E>
U373 M2DMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[1PZkyODBvNECwJO69VQ>? NVmzfnM6PzJxOU[gbC=> NGrMeYp1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= NUPubYtxOjV|N{WyO|E>
U343 NF:1NplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP2dmgyODBvNECwJO69VQ>? NW\WTYVKPzJxOU[gbC=> MVX0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? MWqyOVM4PTJ5MR?=
U87MG-luc2 M3PmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXZN|hWOTByLUSwNEDPxE1? M{ns[lczNzl4IHi= M{XLNpRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NHiweHczPTN5NUK3NS=>
U87 NEnBN2NHfW6ldHnvckBCe3OjeR?= MnnqNlAxKM7:TR?= M4qwblQ5KGh? M4jUXYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? M162dlI2OzN5N{Kx
U251 NUixV3JzTnWwY4Tpc44hSXO|YYm= M1XEbVIxOCEQvF2= MVG0PEBp NX\0WVROcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= MXiyOVM{Pzd{MR?=
A172 NETPVlRHfW6ldHnvckBCe3OjeR?= M1S1S|IxOCEQvF2= M3fYWVQ5KGh? MorZbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? M3vWPVI2OzN5N{Kx
U251 NXT6NFllTnWwY4Tpc44hSXO|YYm= NH6xVIwzODBizszN MWW0PEBp M{fnNolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? NXG4eWVsOjV|M{e3NlE>
A172 MYPGeY5kfGmxbjDBd5NigQ>? M{nRXFIxOCEQvF2= MUC0PEBp NFPhdI1qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{ MnHRNlU{Ozd5MkG=
U87 M4HGV2Z2dmO2aX;uJGF{e2G7 NIHFcWIzODBizszN NWnUe5F2OjRxN{KvNVIxKGh? M17ub4lv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? NGPUcnAzPTN|N{eyNS=>
U251 MYTGeY5kfGmxbjDBd5NigQ>? NHTmUoozODBizszN Mn;FNlQwPzJxMUKwJIg> M3faUolv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MWWyOVM{Pzd{MR?=
A172 NX;jbnRETnWwY4Tpc44hSXO|YYm= NEfienozODBizszN NVXVT4R5OjRxN{KvNVIxKGh? NF7ibG5qdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? MXGyOVM{Pzd{MR?=
SNB19V MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[3JIQ> MX7EUXNQ MorxS2k2OD1|NT63xtEyOiEQvF2= NFjjfpQzPTJ5N{S0NS=>
SNB19M M1jRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XMW|ch\A>? M4LrOmROW09? NX3KNZc3T0l3ME20OlkvQcLzOEig{txO NIC5T2IzPTJ5N{S0NS=>
SNB19VR NFXEd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3nS204KGR? MWXEUXNQ NWn6TmszT0l3ME2yPFAvOsLzMUig{txO MVSyOVI4PzR2MR?=
U373V NI\HbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[5WFch\A>? MUnEUXNQ MmHKS2k2OD14OD6wxtE{OiEQvF2= MU[yOVI4PzR2MR?=
U373M M2[0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfYbG14PyCm NU\hT|FmTE2VTx?= NWmxVnVbT0l3ME2zOlgvP8LzOE[g{txO MkS1NlUzPzd2NEG=
U373VR NHjUWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPoUVI4KGR? NV\JPWhxTE2VTx?= M3v1eGdKPTB;Mki4MljDuTN|IN88US=> MWqyOVI4PzR2MR?=
U87MG NUH6ZXo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDaVW12PyCm NWXaZ21bTE2VTx?= MmC4S2k2OD1|OD6zxtEzOCEQvF2= Mn75NlUzPzd2NEG=
HCT116 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\XO{Bl MYfEUXNQ NFTGPJhIUTVyPUW3PU46yrF|MjFOwG0> MmfRNlUzPzd2NEG=
DLD1 M2LSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmruO{Bl MVPEUXNQ NEPFO3FIUTVyPUWwNU41yrF7MzFOwG0> NXTlW4VnOjV{N{e0OFE>
MRC5 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO3JIQ> NHywdIlFVVOR NWm4NVByT0l3ME20OFkvPMLzODFOwG0> MoXGNlUzPzd2NEG=
SNB19V  NV3iZmhiTnWwY4Tpc44hSXO|YYm= NVfW[W1WOTByIN88UeKhXE2c MUewMVczKGh? MV;pcoNz\WG|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=> MYOyOVI4PzR2MR?=
T98G  NIHVOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1UWtxPS9zMD:xOUDPxE1? M3jLdFI1yqCq Mn21bY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= MlX5NlUzPjJ7NkG=
U251  NYrOR|ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS1M|ExNzF3IN88US=> NXTxT4hXOjUEoHi= MkDpbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= M1GzZVI2OjZ{OU[x
T98G  NYXnRZFNTnWwY4Tpc44hSXO|YYm= M1S1NlE2KM7:TR?= MkPINlTDqGh? M3j3XIlv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= Mn7wNlUzPjJ7NkG=
U251  NVKzZWF{TnWwY4Tpc44hSXO|YYm= M1PVVFE2KM7:TR?= M2Hy[FI1yqCq NYrqbo1bcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz NH7oXIUzPTJ4Mkm2NS=>
U-87 MG NELSSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETBelk4OiCq M3L2VGlEPTB;MD65N{BuVcLi NHPqd3UzPTJ2NUOzNi=>
U-118 MG M4\5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXMO|IhcA>? M3;KT2lEPTB;MT6wOUBuVcLi MUGyOVI1PTN|Mh?=
U87 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXGNlQhcA>? MVnJR|UxRTJ4MD6zOEDPxE4EoB?= MUKyOVE4OzJ|Mx?=
U87 GSLCs Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWyOEBp MUHJR|UxRTd4Nj6xNUDPxE4EoB?= NF7UUmUzPTF5M{KzNy=>
U87MG MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37pSlczKGh? MUnJR|UxRTF3Lk[yOUDPxE4EoB?= MUKyOVA2ODlzNR?=
U251 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjnNVAxNTRyMDFOwG0> M2DPOFQ5KGh? MnLKSG1UVw>? M1vib4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3G4TlI1PjJ|N{O2
U87 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNFAuPDByIN88US=> MXy0PEBp MYLEUXNQ M{fYeIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnKxNlQ3OjN5M{[=
MDA-MB-231-br NInJXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLNNE0yOCEQvF2= MlziOFghcA>? NFrsPItFVVOR MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{TReFI1PjJ|N{O2
HCC-1937 NF;YNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon0NE0{ODBizszN MoHmOFghcA>? M1fQO2ROW09? M2HscIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVOyOFYzOzd|Nh?=
MDA-MB-231 NGDR[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuwMVQxKM7:TR?= MXm0PEBp NWfQSG01TE2VTx?= M4DrbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYLlWYpGOjR4MkO3N|Y>
MDA-MB-468 NXrwS5c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3rS|IxNTVyMDFOwG0> NVzZfVU5PDhiaB?= Mn3ySG1UVw>? MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYeyOFYzOzd|Nh?=
T47D NUOyTGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXMTYcxNTFyMDFOwG0> NILpdY81QCCq NFjVRWVFVVOR M{f5TolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1rmNlI1PjJ|N{O2
MCF7 M{H2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHxUHIxNTFyMECg{txO M1G4Z|Q5KGh? NFXtR2xFVVOR M2C2OolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUDQPWxFOjR4MkO3N|Y>
Hs683 NHHoW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPSVoQxNTFyMECg{txO MVW5OkBp MWHJR|UxRTF{OD65JO69VQ>? NXna[GF2OjR2OUW5NFc>
U87 NWC2bnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XsXFAuOTByMDFOwG0> M{HjNVk3KGh? Mmi2TWM2OD1zOD60OUDPxE1? NV;ke29tOjR2OUW5NFc>
LNZ308 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HLOFAuOTByMDFOwG0> NGXzNVc6PiCq NH;UbHJKSzVyPUOyOk44KM7:TR?= M{PDXlI1PDl3OUC3
U87 Mn60RZBweHSxc3nzJGF{e2G7 M4rCcFExOCEQvF2= MkjsOFghcA>? NHj0dnBFVVOR M4j2folv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= NXGyeGNYOjR2OEG1PFY>
U251  Mor0RZBweHSxc3nzJGF{e2G7 NV7H[pFxOTByIN88US=> MVG0PEBp NFfIW5pFVVOR M3S5S4lv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= NGLqdIwzPDR6MUW4Oi=>
U251 NXfETIwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i4dlI1KGh? Mn7ETWM2OD16Nj6yPgKBkcLz4pEJNU42QCEQvF2= NInwd4wzPDN{Nkm1OC=>
U251 M{HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpW|Q5KGh? MXvJR|UxRTd3LkO05qCKyrIkgJmxMlAzKM7:TR?= NEGxbXYzPDN{Nkm1OC=>
U251 NEjaZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPyO|IhcA>? M3u0TmlEPTB;N{KuOFLjiIoEsfMAjVEvPDVizszN MonlNlQ{OjZ7NUS=
U251 M3XM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn2VJE6PiCq Mkf4TWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= MVmyOFMzPjl3NB?=
T98G M2jzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWwMVc2OCEQvF2= MlL0O|IwQTZiaB?= MmHKbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFnoTHUzPDN{NEC4NC=>
U251-MG NVTUbZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PmZVAuQDByIN88US=> NICzO5U4OiCq NY\LOZFQcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MV6yOFA6OzZ|MB?=
D54-MG M1XzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmwMVgxOCEQvF2= M3yzclczKGh? Ml33bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIDBd2IzPDB7M{[zNC=>
SHG-44 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TWTVExNTJyMDFOwG0> MVi5OkBp M4rWb2lEPTB;OT63N{DDuSB{LkGyJO69VQ>? M1q2eVI1ODZ3NU[5
U373  NULhWnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexNE0zODBizszN M2H2Slk3KGh? M1i0S2lEPTB;MUCuNVMhyrFiMT6wNkDPxE1? M1XRfFI1ODZ3NU[5
HT-29  NETJdG1HfW6ldHnvckBCe3OjeR?= NI\mVmU2ODBizszN NH3ncGgzPC92ODDo MVrlcohidmOnczD0bIUhdGW4ZXzzJI9nKM7|LViyRXjDqA>? MVmyOFA{QDB4OB?=
PC-3  NV\hfW9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWyUmsxNTJ3IN88US=> NXS5T4hEPDhiaB?= NXzJWoJFcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJJBwfGWwdHnheIVlKGK7IHz5Z49x\W6n NFnBRnYzOzd2NkmzOC=>
PC-3  MmjjRZBweHSxc3nzJGF{e2G7 NV\IdFd5OjVizszN NGTuSmw1QCCq NVLETG0xcW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m Ml2xNlM4PDZ7M{S=
T98G NEjQTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HvXVUxNTRyMDFOwG0> MUCxOFQhcA>? NVXiOoxicW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M{nOdFI{PzF3NEm5
U87-MG NXnhZmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP4OpgyODBiwsXN MUC3NkBp NF;T[Y1qdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE MUCyN|Y6Pjd6OB?=
U251-MG NIjsTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLUNVAxKML3TR?= MUi3NkBp NWDLNpV[cW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= NWCyRVF4OjN4OU[3PFg>
LNT-229 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLzN{0yODBizszN NGnCbJUzPCCq M{\CW4lvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlnENlM3Pjd4M{K=
T98G MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TXIRwOTBvN{CwJO69VQ>? NID5PJEzPCCq MWLpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVvZPGh3OjN4Nke2N|I>
U87  MYfGeY5kfGmxbjDBd5NigQ>? NEHzWZUyODBiwsXN MnPMN{Bp M4HJXIVt\X[jdHXzJJRp\SCuZY\lcJMhd2ZicFPob|Eh[W6mIIDDbIsz NIjzcXgzOzZ4N{S2PS=>
HCT116 MlXTSpVv[3Srb36gRZN{[Xl? MoLKNVAxKML3TR?= NYPjTIN6OyCq Mn\rbY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? M334b|I{PjZ5NE[5
HCT3-6 NH2xO4xHfW6ldHnvckBCe3OjeR?= Ml\nNVAxKML3TR?= MmHON{Bp M2XwTYlv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w MoezNlM3Pjd2Nkm=
U-87  MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrYOpYxNTRyIN88US=> MXSxNkBl MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3jCc|I{PjR3N{K5
U-87  NHvhSGxCeG:ydH;zbZMhSXO|YYm= MkLnNE01OCEQvF2= M3zKflMwPiCm MXfpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M1O4TVI{PjR3N{K5
U-87  NETyT4hHfW6ldHnvckBCe3OjeR?= NEXaeXcxNTRyIN88US=> NF75UpQ{NzZiZB?= M2j1SYlv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MkTQNlM3PDV5Mkm=
GB-SCC010 M1K3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LKbFQh\A>? MYXJR|UxRTJ{NjFOwG0> NHv1Sm4zOzZzMke1OS=>
GB-SCC026 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfETWc1KGR? M4e4U2lEPTB;NUOuNUDPxE1? NXf5[GRYOjN4MUK3OVU>
GB-SCC028 M1XRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPjd5pZPCCm NUjYe4Y1UUN3ME2xOlch|ryP MYGyN|YyOjd3NR?=
U87 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K4ZlQh\A>? NYOwbmR5UUN3ME20OU4zKM7:TR?= NHzNTmczOzZzMke1OS=>
U87 stem cell MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHLOEBl M1XQVWlEPTB;Nk[uO{DPxE1? NEjyelczOzZzMke1OS=>

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02977780 Recruiting Glioblastoma Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology, Inc.|Accelerate Brain Cancer Cure February 9, 2017 Phase 2
NCT02689336 Recruiting Glioma|Rhabdomyosarcoma|Osteosarcoma|Medulloblastoma|Neuroectodermal Tumor|Ependymoma|Ewings Sarcoma|Wilms Tumor Washington University School of Medicine August 6, 2016 Phase 2
NCT02455557 Recruiting Glioblastoma|Gliosarcoma Roswell Park Cancer Institute|National Cancer Institute (NCI) May 5, 2015 Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT03018288 Not yet recruiting Glioblastoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 3, 2017 Phase 2
NCT02766270 Recruiting Grade II/III Glioma Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Beijing Shijitan Hospital September 26, 2016 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID